Johan Maertens

Active 1999–2026

259
Papers
46,995
Citations
97
h-index
244
i10-index

Citations

Citations per year for Johan Maertens1989: 1 citations1990: 1 citations1994: 1 citations1996: 1 citations1998: 1 citations2000: 4 citations2001: 16 citations2002: 45 citations2003: 66 citations2004: 101 citations2005: 119 citations2006: 158 citations2007: 242 citations2008: 274 citations2009: 235 citations2010: 316 citations2011: 315 citations2012: 298 citations2013: 226 citations2014: 307 citations2015: 289 citations2016: 351 citations2017: 258 citations2018: 307 citations2019: 1,282 citations2020: 1,452 citations2021: 1,610 citations2022: 1,214 citations2023: 1,061 citations2024: 1,723 citations2025: 835 citations2026: 10 citations1991–1993: no citations, so these years are not shown1995: no citations, so this year is not shown1997: no citations, so this year is not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,209 citing papers, 20.2% of this breakdownGermany: 1,151 citing papers, 7.3% of this breakdownFrance: 1,064 citing papers, 6.7% of this breakdownUnited Kingdom: 932 citing papers, 5.9% of this breakdownItaly: 895 citing papers, 5.6% of this breakdownChina: 746 citing papers, 4.7% of this breakdownSpain: 744 citing papers, 4.7% of this breakdownNetherlands: 722 citing papers, 4.5% of this breakdownBelgium: 476 citing papers, 3% of this breakdownSwitzerland: 453 citing papers, 2.9% of this breakdownAustralia: 424 citing papers, 2.7% of this breakdownCanada: 393 citing papers, 2.5% of this breakdown
0%20.2%Other 29.3%

Fields

  • Medicine88.4%
  • Biochemistry, Genetics and Molecular Biology5.4%
  • Immunology and Microbiology3.4%
  • Agricultural and Biological Sciences0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Engineering0.3%
  • Other1.5%

Topics

  • Antifungal resistance and susceptibility14.3%
  • Fungal Infections and Studies10.4%
  • Acute Myeloid Leukemia Research5.5%
  • Hematopoietic Stem Cell Transplantation4.4%
  • Neutropenia and Cancer Infections3%
  • Cytomegalovirus and herpesvirus research2.8%
  • Other59.6%

Coauthors

All papers

Open in search
  1. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher C. Kibbler, Dimitrios P. Kontoyiannis, Bart Jan Kullberg, Katrien Lagrou, Frédéric Lamoth, Thomas Lehrnbecher, Jürgen Loeffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Kieren A. Marr, Henry Masur, Jacques F. Meis, C Orla Morrisey, Márcio Nucci, Luis Ostrosky‐Zeichner, Livio Pagano, Thomas F. Patterson, John R. Perfect, Zdeněk Ráčil, Emmanuel Roilides, Marcus Ruhnke, Cornelia Schaefer Prokop, Shmuel Shoham, Monica A. Slavin, David A. Stevens, George R. Thompson, José A. Vázquez, Claudio Viscoli, Thomas J. Walsh, Adilia Warris, L. Joseph Wheat, P. Lewis White, Theoklis E. Zaoutis, Peter G. Pappas - Clinical Infectious Diseases 2019 cited by 2,817

  2. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Claus Peter Heußel, C Kibbler, Н Н Климко, Bart Jan Kullberg, Christoph Lange, Thomas Lehrnbecher, Jürgen Löffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Jacques F. Meis, Livio Pagano, Patricia Ribaud, Malcolm Richardson, Emmanuel Roilides, Markus Ruhnke, Maurizio Sanguinetti, Donald C. Sheppard, János Sinkó, Anna Skiada, Maria J. G. T. Vehreschild, Claudio Viscoli, Oliver A. Cornely - Clinical Microbiology and Infection 2018 cited by 1,518

  3. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,206

  4. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Theoklis E. Zaoutis, John E. Bennett - Clinical Infectious Diseases 2008 cited by 4,909

  5. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2015 cited by 972

  6. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2021 cited by 300

  7. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 290

  8. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 1,807

  9. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet 2021 cited by 276

  10. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Intensive Care Medicine 2020 cited by 454

  11. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2018 cited by 205

  12. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn Sasse, Rochelle Maher, Bernhardt Zeiher, Maria J. G. T. Vehreschild - The Lancet Infectious Diseases 2016 cited by 694

  13. Combination Antifungal Therapy for Invasive Aspergillosis

    Authors: , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2015 cited by 500

  14. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

    Authors: , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2018 cited by 339

  15. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marina Linhofer, Jonas Frost, Peter Zechner, Matthias Kochanek, Philipp Eller, Jeffrey D. Jenks, Sara Volpi, Anne‐Pauline Bellanger, P. Lewis White, Gustavo H. Goldman, Paul Bowyer, Antonis Rokas, Sara Gago, Paolo Pelosi, Chiara Robba, Jean‐Pierre Gangneux, Cornelia Lass-Floerl, Marina Machado, Patricia Muñóz - Clinical Microbiology and Infection 2021 cited by 230

  16. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José A. Vázquez, Joost Wauters, Erika Asperges, Andrea Cortegiani, Cecilia Grecchi, Ilias Karaiskos, Clément Le Bihan, Toine Mercier, Klaus Leth Mortensen, Maddalena Peghin, Chiara Rebuffi, Sofía Tejada, Antonio Vena, Valentina Zuccaro, Luigia Scudeller, Thierry Calandra, Claire Roger, Christian Eckmann, Jean‐Pierre Gangneux, Esther Segal, Geoffrey W. Coombs, Andreas Voß - Intensive Care Medicine 2024 cited by 171

  17. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 822

  18. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennita Slomp, Alexander N. Snel, Marie‐Christiane Vekemans, Bob Löwenberg, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis - Journal of Clinical Oncology 2013 cited by 449

  19. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2009 cited by 719

  20. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

    Authors: , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2016 cited by 409

  21. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2008 cited by 460

  22. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

    Authors: , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2016 cited by 295

  23. Antifungal drugs: What brings the future?

    Authors: , , , , , , - Medical Mycology 2019 cited by 219

  24. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

    Authors: , , , , , , , , , - New England Journal of Medicine 2019 cited by 181